Background Macrophages and dendritic cells lacking the transcription factor nuclear factor kappa B p50 are skewed toward a proinflammatory phenotype, with increased cytokine expression and enhanced T cell activation; additionally, murine melanoma, fibrosarcoma, colon carcinoma, and glioblastoma grow slower in p50−/ − mice. We therefore evaluated the efficacy of p50-negative immature myeloid cells (p50-IMCs) adoptively transferred into tumor-bearing hosts. Immature cells were used to maximize tumor localization, and pretreatment with 5-fluorouracil (5FU) was examined due to its potential to impair marrow production of myeloid cells, to target tumor myeloid cells and to release tumor neoantigens.
Methods Wild-type (WT)-IMC or p50-IMC were generated by culturing lineage-negative marrow cells from WT or p50−/ − mice in media containing thrombopoietin, stem cell factor and Flt3 ligand for 6 days followed by monocyte colony-stimulating factor for 1 day on ultralow attachment plates. Mice inoculated with Hi-Myc prostate cancer (PCa) cells or K-RasG12D pancreatic ductal carcinoma (PDC)-luciferase cells received 5FU followed 5 days later by three doses of 107 immature myeloid cells (IMC) every 3–4 days.
Results PCa cells grew slower in p50−/ − mice, and absence of host p50 prolonged the survival of mice inoculated orthotopically with PDC cells. IMC from Cytomegalovirus (CMV)-luciferase mice localized to tumor, nodes, spleen, marrow, and lung. 5FU followed by p50-IMC slowed PCa and PDC tumor growth, ~3-fold on average, in contrast to 5FU followed by WT-IMC, 5FU alone or p50-IMC alone. Slowed tumor growth was evident for 93% of PCa but only 53% of PDC tumors; we therefore focused on PCa for additional IMC analyses. In PCa, p50-IMC matured into F4/80+ macrophages, as well as CD11b+F4/80−CD11c+ conventional dendritic cells (cDCs). In both tumor and draining lymph nodes, p50-IMC generated more macrophages and cDCs than WT-IMC. Activated tumor CD8+ T cells were increased fivefold by p50-IMC compared with WT-IMC, and antibody-mediated CD8+ T cell depletion obviated slower tumor growth induced by 5FU followed by p50-IMC.
Conclusions 5FU followed by p50-IMC slows the growth of murine prostate and pancreatic carcinoma and depends on CD8+ T cell activation. Deletion of p50 in patient-derived marrow CD34+ cells and subsequent production of IMC for adoptive transfer may contribute to the therapy of these and additional cancers.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Myeloid cells are a heterogeneous group of cells that belong to the innate immune system. Among them, macrophages and dendritic cells (DCs) directly control T cell responses. Multiple solid tumors secrete chemokines, for example, CCL2, and cytokines, such as monocyte colony-stimulating factor (M-CSF) or interleukin (IL)-4, that attract circulating monocytes and induce their maturation into M2-polarized tumor-associated macrophages (TAMs); M2 TAMs suppress antitumor T cell immunity and secrete tumor-promoting growth factors, proangiogenic VEGF, and proinvasive matrix metalloproteases.1 2 M-CSF receptor tyrosine kinase inhibitors that induce proinflammatory M1 TAM activation are under clinical investigation; however, resistance to such agents can arise via tumor secretion of alternative M2-polarizing cytokines.3–5 Targeting non-redundant transcription factors critical for maintenance of the M2 gene expression programme may prove more effective.
Nuclear factor kappa B (NF-κB) subunits dimerize and bind DNA via their Rel homology domains. Under basal conditions, NF-κB p65 (RelA) and c-Rel are held in the cytoplasm by IκB; however, NF-κB p50 (NF-κB1, p50), which lacks a transactivation domain and has much lower affinity for IκB, enters the nucleus to bind DNA and repress transcription in cooperation with histone deacetylases (HDACs) and Bcl-3. Proinflammatory cytokines such as tumor necrosis factor alpha (TNFα) initiate canonical signalling, leading to phosphorylation of IκB followed by ubiquitination and proteasomal degradation, thereby allowing complexes such as p65:p65 and p65:p50 to enter the nucleus, displace repressive p50:p50 homodimers, and induce proinflammatory gene expression.6–8
In myeloid cells with reduced or absent p50, NF-κB target genes are de-repressed due to the absence of chromatin-bound p50:p50:HDAC or p50:p50:Bcl-3 complexes. Proinflammatory gene induction by p50 (Nfkb1) gene deletion or RNA knockdown leads to activation of macrophages, as well as DCs, favouring T cell activation.9–14 Melanoma, fibrosarcoma, colon cancer, and glioblastoma cells grow slower in syngeneic p50−/ − than wild-type (WT) recipients; TAMs are reprogrammed from M2 to M1; and tumor T cells are more activated.9 15 16 Prostate cancer (PCa) and pancreatic ductal carcinoma (PDC) also contain evident M2 TAMs, which are correlated with poor prognosis.17 18 Adding to these findings, we demonstrate slower growth of subcutaneous Hi-Myc PCa and prolonged survival after orthotopic inoculation of K-RasG12D PDC into p50−/ − compared with WT hosts.
Specifically inhibiting p50 at the protein level without affecting the homologous RelA or c-Rel may prove problematic, and p50 inhibition in tumor cells may favour tumor growth.6 We ultimately envision a cellular therapy wherein patient-derived myeloid cells are expanded ex vivo while targeting their p50 gene or mRNA and then reinfused. Infusion of murine marrow monocytes polarized to an immunosuppressive state reduces graft versus host disease, with biallelic mutation in the ASC inflammasome gene providing greater protection by preventing in vivo conversion to the M1 phenotype.19 Analogously, we expect that myeloid cells lacking p50 will be ‘locked’ in an activated antitumor state. To model this approach, we have expanded lineage-negative (Lin−) murine marrow cells from WT or p50−/ − mice for 6–8 days using thrombopoietin (TPO), stem cell factor (SCF), and Flt3 ligand (FL), cytokines which maintain stem and progenitor cell immaturity. Next, cells were cultured with M-CSF for 1 day on ultralow attachment plates to generate immature myeloid cells (IMC) and to prevent macrophage maturation.20 IMCs were then infused, avoiding provision of mature macrophages that might less efficiently reach the tumor. We also evaluated pretreatment with 5-fluorouracil (5FU) at a dose that induces a nadir of host white blood cells starting 4 days later and lasts 1 week,21 analogous to lymphodepletion prior to adoptive T cell transfer. In addition, 5FU targets immunosuppressive tumor myeloid cells22 and may release PCa or PDC neoantigens to further enhance antitumor response.
We have determined that 5FU followed by three infusions of p50-negative IMC (5FU/p50-IMC) slows the growth of Hi-Myc PCa and K-RasG12D PDC tumors, in contrast to 5FU/WT-IMC, p50-IMC alone, or 5FU alone. Infused cells mature in vivo into activated tumor and lymph node macrophages and conventional dendritic cells (cDCs). Additionally, 5FU/p50-IMC increased numbers of activated tumor CD8+ T cells, and CD8+ T cell depletion eliminated the therapeutic efficacy of 5FU/p50-IMC.
Male WT C57BL/6 (B6) CD45.1 or CD45.2 mice of 8–12 weeks were obtained from Charles River Laboratory (Kingston, New York, USA) as PCa recipients. Male and female WT or p50−/ − B6 mice of 8–16 weeks were used as IMC donors. Male WT albino B6 mice (#58) of 8–12 weeks to be used for PDC recipients, p50−/ − mice (#6097), and B6 Cytomegalovirus (CMV)-Luc mice (#25854) were obtained from Jackson Laboratory (Bar Harbor, Maine, USA). Mice were housed in individually ventilated cages at 22°C with a 12 hours’ light/dark cycle, five mice per cage, and were given acidified water and Envigo 2018SX autoclaved feed. Mice of the same sex and age, 24–26 g, were used as cancer cell recipients.
Tumor cell inoculation and in vivo monitoring
B6 Hi-Myc PCa cells and UN-KC-6141 KRasG12D;Pdx1-Cre PDC cells have been described and were kindly provided by BW Simons and SK Batra, respectively.23 24 PCa cells were maintained in WT male mice by serial subcutaneous (SQ) passage every 3–4 weeks or inoculated into WT or p50-/- male mice for experiments as described.23 In brief, PCa tumors were harvested after euthanasia, minced, placed in Dulbecco’s modified Eagle medium (DMEM)/F12 with 10% fetal bovine serum (FBS), Collagenase/Hyaluronidase, Dispase, and DNase I (Stem Cell Technologies). After incubation at 37°C for 1 hour, cells were passed through a 40 µM strainer, pelleted, resuspended at 2×106 viable cells per 100 µL phosphate-buffered saline (PBS)/mouse, and injected into the flanks of recipients. Tumor growth was monitored 2- to 3-times weekly using callipers, with tumor volumes estimated as length x width x height x π/6.23 Mice were euthanized when tumors reached 2.0 cm in maximal linear dimension or became ulcerated.
PDC cells were cultured in vitro using DMEM with 10% FBS, 1% non-essential amino acids, 1% sodium pyruvate, and penicillin (100 U/mL)-streptomycin (100 µg/mL). PDC-Luc cells were generated by transfection with NotI-linearized pGL4.51-CMV-Luc2neo (Promega) using Lipofectamine 2000 (Invitrogen) followed by selection in 0.6 mg/mL G418, subcloning by limiting dilution, and screening by luciferase assay to identify a single clone that was used for these studies. For orthotopic PDC inoculation, after inducing anaesthesia with ketamine and xylazine, a 1 cm incision was made in the left flank and a 5 mm incision in the peritoneum. The entire pancreatic body together with spleen was pulled out using blunt-nose forceps, 0.5×106 PDC in 40 µl of 1:1 PBS:Matrigel (Corning 354234) was injected into the pancreatic tail using a Hamilton syringe with a 30 g needle, and the muscle layer and skin were closed with 4–0 absorbable sutures. For PDC-Luc tumor imaging, after shaving the abdominal wall mice were injected intra-peritoneally (IP) with luciferin (150 µg/g) in PBS; 10 min later mice were anaesthetized with isofluorane-oxygen gas and imaged using the Spectrum in vivo imaging system (IVIS, Perkin Elmer). To allow repeated imaging of albino mice, the shaved abdominal wall was treated with Nair every 2 weeks.
To generate IMC, marrow mononuclear cells were obtained by crushing the long bones, hips, and spine in PBS with 2% FBS. Red blood cells were lysed using ammonium chloride. Marrow was then lineage-depleted using biotin-conjugated B220, Gr-1, CD11b, Ter119, and CD3 mouse antibody Lineage Cocktail (BD Biosciences), anti-biotin microbeads, and LD columns (Miltenyi Biotec). Lin− cells were then cultured for 6-8 days with Iscove’s Modified Dulbecco Medium (IMDM), 10% heat-inactivated FBS, murine SCF (30 ng/mL), murine TPO (10 ng/mL), and murine FL (30 ng/mL), followed by transfer to IMDM with 10% HI-FBS and murine M-CSF (20 ng/mL), or alternatively with granulocyte-monocyte colony-stimulating factor (GM-CSF, 1 ng/mL) and FL (30 ng/mL), for 24 hours on Ultra-low attachment six-well plates (Corning, #3471). Non-adherent cells, designated as IMC, were then collected and washed with PBS prior to infusion of 107 cells in 200 µL PBS per dose by tail vein injection. 5FU was given at 150 mg/kg IP using a 7.5 mg/mL solution in normal saline 5 days prior to the first IMC injection. To deplete CD8+ T cells, mice received rat-anti-CD8 antibody (Bio-X-Cell, BE0223) at 100 ug/dose IP twice weekly beginning 1 day prior to the first IMC injection.
PCa tumors were dissociated as done for cell inoculation; lymph node and spleens were treated with Collagenase/Hyaluronidase for 30 min and then passed through a 40 µL cell strainer. Marrow cells were subjected to red cell lysis. To induce T cell activation, total tumor cells were incubated for 4 hours in DMEM/10% FBS with Cell Stimulation Cocktail (eBioscence) containing phorbol myristate acetate (PMA)/ionomycin with brefeldin A and monensin protein transport inhibitors, or with the inhibitors alone. These cell populations and IMC were stained with surface antibodies on ice after 15 min 1:50 FcγR blockade (eBioscience). Cells were analyzed by flow cytometry (FC) using an LSRFortessa flow cytometer (BD Biosciences) gating on cells that excluded Live/Dead Aqua dye (ThermoFisher). For T cells, intracellular interferon γ (IFNγ) staining was done after surface staining using the FoxP3 kit (eBioscience). Antibodies used were anti-CD45.1-PE (A20), anti-CD45.2-BV650 (104), anti-Ly6G-FITC (1A8), anti-CD11c-PE/Dazzle594 (N418), anti-F4/80-APC (BM8), anti-Ly6C-AF700 (HK1.4), anti-MR-PE-Cy7 (068C2), anti-Flt3-BV421 (A2F10), anti-CD115-PE (AFS98), anti-CD3-AF488 (17A2), anti-CD8-BV650 (53–6.7), and anti-IFNγ-APC (XMG1.2) from BioLegend, anti-CD11b-PerCP-Cy5.5 (M1/70), anti-CD19-AlexaFluor 647 (1D3), and anti-CD4-BUV496 (GK1.5) from BD Biosciences, and anti-Major Histocompatibility Complex II(MHCII)-eFluor450 (M5/114.15.2) and anti-PD-1-PE-Cy7 (J43) from eBioscience. IMC cell morphology was visualized by Wright’s-Giemsa staining of cell cytospins.
Tumor volumes at a given time point and T cell subsets were compared using the Student t-test (Excel 2016), with means and standard errors (SE) shown. In addition, tumor growth was fit to an exponential model using linear mixed effects analysis package lme4,25 with pairwise p-values obtained at specific time points after correcting for multiple comparisons using Tukey’s method using emmeans V.18.104.22.168 Adjusted p value<0.05 was considered significant. Survival curves were generated using Survival Analysis in R V.2.3827 and compared using the Log Rank test. In most instances, five mice were studied per condition in each experiment. The number of experimental replicates, the total number of mice analyzed per experimental condition, and whether results shown are from combining data from more than one replicate are delineated in the figure legends.
Absence of host p50 slows PCa growth and prolongs survival after PDC inoculation
We first evaluated whether absent host p50 impacts murine PCa and PDC tumor growth. Hi-Myc PCa cells were inoculated into the flanks of syngeneic B6 WT or p50-/- mice and tumor sizes were monitored once they became palpable, with volume of at least 0.015 cm3, which first occurred on day 21 (figure 1A, left). To account for all the data, measured tumor volumes were fit to an exponential model of tumor growth, with the resulting semi-log plots of tumor volume versus time and their 95% confidence intervals shown (figure 1A). Comparison of tumor sizes, as predicted by the exponential model, demonstrates a statistically significant, 3- to 16-fold, reduction in PCa tumor volume in the p50-/- recipients between days 25 and 62, including 3.9-fold reduction (p=0.007) on day 33 (figure 1A, right).
K-RasG12D PDC cells were inoculated orthotopically into the pancreas of syngeneic B6 WT or p50-/- mice and survival was monitored (figure 1B). p50-/- hosts survived significantly longer, with the time to 50% survival increasing from 28 to 58 days. These findings demonstrate that both Hi-Myc PCa and K-RasG12D PDC tumors grow slower in mice lacking p50, as seen previously for melanoma, fibrosarcoma, colon cancer, and glioblastoma.9 15 16
Generation and characterization of IMCs
We and others have identified a role for p50 in maintaining the suppressive M2 phenotype of myeloid cells.9 16 In an effort to exploit this role and develop a clinically-relevant therapy, we generated myeloid cells from p50-/- marrow that could serve as a model for adoptive cell therapy in PCa, PDC, and potentially additional cancers. Terminal differentiation of myeloid cells increases expression of adhesive receptors which might limit tumor localization, as seen in previous macrophage-based cell therapies.28 We therefore used less mature cells. Lin− bone marrow mononuclear cells from WT or p50-/- mice were expanded in media containing SCF, TPO, and FL, cytokines that maintain stem/progenitor cell immaturity. 2.5–5×106 Lin− cells were obtained per mouse, and these expanded ~15 fold over 6 days, with Lin− cells from p50-/- mice generating ~20% more cells than those from WT mice. To promote monocytic maturation while minimizing macrophage formation, expanded cells were then placed in media containing M-CSF for only 1 day. Resulting IMCs generated from WT or p50-/- marrow were designated WT-IMC or p50-IMC, respectively.
Wright-Giemsa-stained cell cytospins revealed that culture in SCF, TPO, and FL for 6 days produced a blast-like morphology, and culture for one additional day in M-CSF generated cells with an immature monocyte-like morphology (figure 2A and online supplementary figure S1A). Flow cytometry (FC) indicates that the vast majority of both WT-IMC and p50-IMC express the pan-myeloid surface protein CD11b and lack Ly6G, CD19, and CD3, proteins found on mature neutrophils, B cells, and T cells, respectively (figure 2B). Staining for Flt3/Flk2 (FL receptor) and CD115 (M-CSF receptor) revealed a Flt3hi population comprising 11% of p50-IMC and 6% of WT-IMC, and a CD115hi population comprising 72% of p50-IMC and 65% of WT-IMC (figure 2C and online supplementary figure S1B). Flt3 is expressed on DC precursors, and further analysis shows that in the Flt3hi population, 68% of p50-IMC and 81% of WT-IMC co-express CD11c and MHCII, consistent with their having DC potential. In the CD115hi population, only 28% of p50-IMC and 43% of WT-IMC co-express CD11c and MHCII. Additionally, within the CD115hi population 47% of p50-IMC and 67% of WT-IMC express Ly6C, a protein found on both monocytes and macrophages, and the mature macrophage marker F4/80 is only present on 11% of CD115hi p50-IMC and 15% of CD115hi WT-IMC (figure 2C and online supplementary figure S1B).
To evaluate the ability of IMC to reach tumors, IMC were generated from CMV-Luc mice (Luc-IMC). We administered 5FU to WT mice that had been inoculated with PCa or PDC. 5FU was chosen as its effects on murine blood counts are well-defined.21 Five days later, at the 5FU-induced nadir of blood counts, we infused Luc-IMC, which were then visualized by IVIS after an additional 2 days (figure 2D). Luc-IMC were evident in PCa and PDC tumors as well as the lungs, spleen, and femurs, but not in heart or liver; the bioluminescence signal in the PDC tumor was ~2.5 fold higher than that of lung or spleen (online supplementary figure S1C).
5Fu followed by p50-IMC slows PCa tumor growth
We next evaluated the ability of p50-IMC to slow PCa tumor growth, postulating that a preceding dose of 5FU would enhance p50-IMC efficacy. Hi-Myc PCa was inoculated into the flanks of syngeneic B6 male mice. Thirteen days later, when tumors were just palpable, mice received a single dose of 5FU, followed by three intravenous injections of 107 WT-IMC or p50-IMC on days 18, 21, and 25, as diagrammed (figure 3A, top). Additional groups of mice received 5FU alone, p50-IMC alone, or neither. tumor volumes measured at individual time points for each mouse in these five experimental groups are shown (figure 3A, bottom). Measured tumor volumes were fit to an exponential model of tumor growth (figure 3B). Between days 19 and 35, expected mean tumor volumes for the 5FU/p50-IMC group were 3- to 10-fold lower than those for both the 5FU/WT-IMC and 5FU alone groups, with p=0.0001 on day 29. We also compared the measured tumor volumes on day 28 or 29 between these groups. At this time, the mean volume of tumors in the 5FU/p50-IMC group was 3-fold lower than that for the 5FU group (p<0.001), and 4-fold lower than that of the 5FU/WT-IMC group (p<0.0001). Of note, this analysis underestimates the true differences in tumor sizes because four tumors in the 5FU group and four tumors in the 5FU/WT-IMC group had already reached 2 cm and required euthanasia prior to day 28 (figure 3C, top). These data indicate that adoptive transfer of p50-IMC, but not WT-IMC, slows PCa tumor growth when administered after a dose of 5FU.
Comparison of modelled tumor growth between the untreated and p50-IMC alone groups revealed no significant difference in expected mean tumor volumes between day 15 and day 38, whereas 5FU/p50-IMC lead to significantly smaller (3- to 50-fold) expected mean tumor volumes on each of these days. Comparison of actual tumor volumes on day 25 confirms that there exists no difference between no treatment and p50-IMC alone; conversely, the mean tumor volume for the 5FU/p50-IMC group is 9-fold lower than that of the p50-IMC alone group (figure 3C, bottom). Thus, p50-IMC does not slow Hi-Myc PCa tumor growth without preceding 5FU.
Since p50-IMC obtained by culture for 6 days with TPO/SCF/FL and then for 1 day in M-CSF may include potential DC precursors, we examined whether culture with FL and low-dose GM-CSF rather than M-CSF could augment anti-tumor efficacy, as this cytokine combination favours DC formation from cultured marrow cells.29 p50-IMC(GM+FL) retained an immature monocyte morphology, although with increased cytoplasmic granulation (online supplementary figure S1D). FC of p50-IMC(GM+FL) revealed a similar pattern of surface marker expression to that obtained with M-CSF, except that the Flt3hi population was less abundant, potentially reflecting down-regulated surface Flt3 due to excess FL (online supplementary figure S1E). In addition, the CD115hi population contained 2-fold increased percentage of F4/80+ cells (30% vs 15%), perhaps reflecting more rapid maturation. PCa tumor growth in individual mice treated with 5FU on day 13 followed by p50-IMC(GM+FL) on days 18, 21, and 25 is shown (figure 4A). 5FU/p50-IMC(GM+FL) data were obtained in the same experiment as a subset of data shown in figure 3 using 5FU alone and 5FU/p50-IMC(M-CSF). Tumor volumes for these groups were fit to an exponential model (figure 4B), and measured tumor volumes on day 25 were compared (figure 4C), revealing that p50-IMC generated using GM+FL are equally effective, but not more effective, than those generated using M-CSF.
We also examined whether a lower dose of p50-IMC per intravenous injection would be as effective as 107 IMC per dose. Cohorts of mice inoculated with PCa received a dose of 5FU on day 13 followed by three infusions of p50-IMC generated using M-CSF at either 4×106 or 1×106 cells per dose. Tumor growth in individual mice for these two groups is shown (figure 4D). The 4×106 cell dose appeared more effective than the 1×106 cell dose. Analysis of the 5FU/p50-IMC(4E6) data in comparison with 5FU/p50-IMC(1E7) and 5FU data from figure 3 using the exponential model reveals that 5FU followed by p50-IMC(4E6) is not significantly better than 5FU alone between day 15 and day 40 (figure 4E), although a trend towards increased efficacy may exist, as indicated also by comparing tumor volumes on day 23, with a 2-fold (p=0.12) difference (figure 4F). These data also demonstrate that 5FU/p50-IMC(1E7) is more effective than 5FU/p50-IMC(4E6).
5FU followed by p50-IMC slows PDC tumor growth in 50% of mice
We also examined whether 5FU followed by M-CSF-generated p50-IMC could slow PDC tumor growth. Luciferase-expressing KRasG12D PDC was inoculated into the pancreatic tail of syngeneic albino B6 mice. Use of albino mice allows serial monitoring of tumor size by IVIS imaging, as requisite shaving of abdominal hair in black B6 mice leads to cutaneous pigment accumulation that obstructs imaging. In Experiment 1, 5FU was administered on day 7, followed by 107 p50-IMC on days 12, 15, and 19. In an effort to initiate therapy when tumors were smaller, in Experiments 2 and 3, 5FU was given on day three followed by WT-IMC or p50-IMC on days 8, 11, and 14, as diagrammed (figure 5A). In Experiment 1, two of five tumors manifested remarkable ~10 fold shrinkage in response to 5FU/p50-IMC, as estimated from relative tumor bioluminescence (and confirmed by abdominal examination); this was not evident in any of the tumors exposed to 5FU alone (figure 5B, left). In Experiment 2, two of five tumors showed 2- to 3-fold shrinkage from maximal size in response to 5FU/p50-IMC, with four of five tumors showing no response to 5FU/WT-IMC (figure 5B, center). In experiment 3, four of five tumors responded to 5FU/p50-IMC more effectively than to 5FU/WT-IMC (figure 5B, right). Data from Experiments 2 and 3 were fit to an exponential model of tumor growth, with resulting semi-log plots of tumor volume versus time shown (figure 5C). Expected mean tumor volumes as predicted by the exponential model for the 5FU/p50-IMC group were 3-fold lower than those for the 5FU/WT-IMC group between days 11 and 21, with p=0.014 on day 14 as shown. We also compared relative tumor bioluminescence on day 14 between the 5FU/WT-IMC and 5FU/p50-IMC groups from Experiments 2 and 3 (figure 5D). At this time, the mean tumor bioluminescence in the 5FU/p50-IMC group was 3-fold lower than that of the 5FU/WT-IMC group (p=0.0047). Overall, these data demonstrate that 5FU followed by p50-IMC is effective against PDC, in some cases inducing substantial transient regression. However, the response of K-RasG12D PDC was less uniform than that of Hi-Myc PCa. Due to this variability, we focused on PCa for further analysis.
p50-IMC generate PCa tumor and draining lymph node macrophages and DCs
To evaluate myeloid cells that develop from a single dose of IMC, CD45.1+ B6 mice inoculated with Hi-Myc PCa received 5FU on day 13 followed by 107 CD45.2+ p50-IMC or WT-IMC on day 18, with isolation of tumor and inguinal draining lymph nodes 2 days later, as diagrammed (figure 6A). As IMC contribution to total tumor or lymph node CD11b+ myeloid cells was low, FC data acquired individually from four WT-IMC and five p50-IMC mice were pooled to generate the flow plots and populations frequencies shown. WT-IMC accounted for 0.8% of tumor and 1.3% of lymph node CD11b+ myeloid cells, whereas p50-IMC comprised a higher proportion at 1.5% and 1.8%, respectively (figure 6B). When data from the four WT-IMC and five p50-IMC mice are compared, the increased contribution of p50-IMC to nodal myeloid cells is significant (p=0.007). Consistent with data obtained with Luc-IMC, p50-IMC also localized to spleen and marrow, where they formed 7.7% and 11% of CD11b+ myeloid cells, respectively (online supplementary figure S2a). Only 1.3% of tumor and 1.5% of nodal myeloid cells derived from p50-IMC were Ly6G+ neutrophils, while 2.2% of tumor and 5.8% of lymph node myeloid cells derived from WT-IMC were Ly6G+ (online supplementary figure S2b).
The F4/80 macrophage marker was expressed on 53% of tumor myeloid cells derived from WT-IMC and 79% of those derived from p50-IMC (p=0.001); in lymph nodes, however, the frequencies of IMC-derived F4/80+ macrophages (88% vs 78%) were not significantly different (figure 6C). A substantial fraction of F4/80+ macrophages also expressed Ly6C, which is present on inflammatory monocytes and on both immune-activating and suppressive macrophages.30 As activated macrophages can co-express Ly6C with MHCII, we analyzed both markers (figure 6D). WT-IMC-derived macrophages co-expressed Ly6C and MHCII to a similar extent as p50-IMC-derived macrophages (23% vs 20% in tumor and 38% vs 32% in lymph nodes), both not significant (NS). We also evaluated F4/80+ macrophages for mannose receptor (MR), a marker of tumor-promoting M2-polarized macrophages (figure 6E). In p50-IMC, macrophage MR was increased in tumor (49% vs 12%, p=0.001) and decreased in lymph node (6% vs 13%, NS) compared with WT-IMC.
In addition to F4/80+ macrophages, IMC-derived myeloid cells included a population of F4/80-Ly6C- cells; in tumor, their frequency was higher in WT-IMC than p50-IMC (32% vs 19%), whereas in lymph node their frequency was lower in WT-IMC than p50-IMC (7% vs 16%). F4/80-Ly6C- cells were further evaluated for CD11c and MHCII, markers co-expressed on activated DCs (figure 6F). Strikingly, 94% of p50-IMC-derived tumor F4/80-Ly6C- cells co-expressed the CD11c and MHCII DC markers, compared with only 2% of WT-IMC-derived cells (p<0.001). Although the 73% frequency of p50-IMC-derived and 70% frequency WT-IMC-derived CD11c+MHCII+ DCs were similar in lymph node (figure 6F), the 2.3-fold increased frequency of the parent F4/80-Ly6C- population indicates an overall increase in DCs derived from p50-IMC. Perhaps the greater overall frequency of CD45.2+ p50-IMC in the tumor and lymph node and the increased ability of p50-IMC to generate CD11c+MHCII+ cDCs in tumor and lymph node accounts, in part, for the enhanced anti-tumor efficacy of p50-IMC compared with WT-IMC.
We also evaluated the effects of 5FU/p50-IMC on host CD45.1+ myeloid cells. To establish a baseline, we characterized myeloid cell surface phenotypes in four tumor-bearing mice that did not receive 5FU or IMC (online supplementary figure S3a). 5FU/p50-IMC increased total tumor F4/80+ macrophages from 79% in untreated to 96% (p<0.001) in treated mice (online supplementary figure S3b); however, among F4/80+ macrophages (online supplementary figure S3c), the proportion of Ly6C+MHCII+ macrophages was reduced from 51% to 3% (p<0.001). In lymph nodes, 5FU/p50-IMC increased F4/80+ macrophages from 42% to 53% (p=0.04), and reduced the Ly6C+MHCII+ macrophage subpopulation from 66% to 9% (p<0.001). 5FU/p50-IMC increased the proportion of MR+ macrophages from 23% to 59% (p=0.001) in tumor and from 26% to 43% (p=0.006) in lymph nodes (online supplementary figure S3d). As shown (online supplementary figure S3e), 5FU/p50-IMC did not significantly impact the proportion of F4/80-C11c+MHCII+ DCs in tumor (31% vs 24%), but reduced this proportion in lymph nodes (55% vs 23%, p<0.001). Finally, only 6.5% of tumor and 3.0% of nodal myeloid cells were Ly6G+ (online supplementary figure S3f). In sum, activation of host tumor or lymph node myeloid cells was not evident on day 20 in response to 5FU/p50-IMC.
CD8+ T cell depletion attenuates the efficacy of 5FU/p50-IMC
To evaluate the effect of 5FU/p50-IMC on host T cells, B6 mice inoculated with Hi-Myc PCa received 5FU on day 13 and then p50-IMC or WT-IMC on days 18, 21, and 25, followed by tumor isolation and analysis on day 30, as diagrammed (figure 7A, top). Day 30 analysis was chosen to allow time for T cell activation after the final p50-IMC infusion. CD4+ T cells represented ~4% of viable cells within the tumor after either 5FU/WT-IMC or 5FU/p50-IMC. CD8+ T cells, however, which represented 3% of viable tumor cells after 5FU/WT-IMC, were 5-fold increased to 15% of viable tumor cells after 5FU/p50-IMC (figure 7A, left). Intracellular IFNγ staining demonstrated that~16% of CD8+ T cells derived from tumors exposed to 5FU/WT-IMC and ~18% of CD8+ T cells in tumors treated with 5FU/p50-IMC were in an activated state at baseline. On PMA/ionomycin stimulation, the proportion of IFNγ+ CD8+ T cells increased 1.5-fold in mice receiving WT-IMC and nearly 3-fold in mice receiving p50-IMC (figure 7A, right). Together, the data for total and IFNγ+ CD8+ T cells indicates that 5FU/p50-IMC increases the total number of activated, tumor-associated CD8+ T cells and that these cells have a greater capacity to respond to signals that induce further T cell activation.
Given the striking increase in PCa tumor CD8+ T cells in mice receiving 5FU/p50-IMC, we evaluated whether the efficacy of 5FU/p50-IMC was dependent on CD8+ T cells. B6 mice inoculated with Hi-Myc PCa received 5FU on day 13 followed by p50-IMC on days 18, 21, and 25. One group of mice also received twice weekly injections of anti-CD8 antibody to deplete CD8+ T cells, beginning on day 17, as diagrammed (figure 7B, top). Tumor volumes measured at individual time points for each mouse in these two experimental groups are shown (figure 7B, bottom). Data for mice that did not receive CD8 antibody comprise a subset of those shown in figure 3 and were obtained in the same experiments as the antibody-treated group. Three mice that developed ulceration prior to initiation of antibody treatment were censored from analysis. The data were fit to an exponential model of tumor growth, with the resulting semi-log plots of tumor volume versus time and their 95% confidence intervals shown (figure 7C). Expected mean tumor volumes for the CD8 antibody-treated group were significantly higher (3- to 10-fold) than those for the control group between days 25 and 36, with p=0.006 on day 29 as shown. Comparison of measured tumor volumes on day 28 indicates a>4 fold increase in mean tumor size consequent to CD8 antibody treatment (figure 7D). We also evaluated the effect of CD8 antibody exposure, beginning on day 17, on PCa tumor growth in mice that did not receive 5FU or IMC. Although FC confirmed effective CD8+ T cell depletion, there was no significant increase in tumor growth rate in the group that received CD8 antibody compared with the control group (online supplementary figure S4).
The key findings of this study are the following: 1) PCa and PDC cells grow slower in mice lacking NF-κB p50, as seen previously for melanoma, fibrosarcoma, colon cancer, and glioblastoma9 15 16 ; 2) expansion of marrow myeloid progenitors from p50-/- mice followed by transfer to M-CSF for 1 day yields IMC that localize to PCa or PDC tumors, regional lymph nodes, marrow, spleen, and lung; 3) administration of 5FU followed by adoptive transfer of p50-IMC, but not WT-IMC, slows the growth of a larger majority of subcutaneous PCa tumors and approximately half of orthotopic PDC tumors, often inducing striking PDC regression in responders; 4) p50-IMC generated using low-dose GM-CSF and FL to favour DC formation also slows PCa growth; 5) p50-IMC generate activated tumor and lymph node macrophages and DCs, but do not activate endogenous tumor myeloid cells; and 6) p50-IMC induce CD8+ T cell activation, and CD8+ T cell depletion reduces efficacy of p50-IMC. p50-IMC was not effective without preceding 5FU, potentially reflecting the ability of 5FU to decrease competition from marrow production of blood monocytes, to deplete immune-suppressive tumor myeloid cells, or to release tumor neoantigens that contribute to CD8+ T cell activation.21 22 Indeed, our data show that PCa tumors grew slower on average in 5FU compared with no therapy. In the clinical setting, a chemotherapy agent other than 5FU might be chosen that both transiently reduces marrow blood cell production and has efficacy against the patient’s malignancy.
Paralleling our finding that efficacy of 5FU/p50-IMC is diminished on CD8+ T cell depletion, simultaneous depletion of CD4+ and CD8+ T cells increased the burden of colon cancer in p50-/- mice to that of WT mice in response to azoxymethane/dextran sodium sulfate exposure,15 and CD4+ T cell depletion fully and CD8+ T cell depletion partially eliminated the survival advantage of p50-/- mice inoculated intra-cranially with glioblastoma.16
Adoptive transfer of activated macrophages has been evaluated in cancer patients, as recently reviewed.28 In the majority of trials, blood monocytes collected by leukopheresis were matured and activated by culturing for 6 days in GM-CSF and then for 18 hours with IFNγ. Although well tolerated, the majority of Indium111-labelled macrophages localizing to the lung and there was minimal anti-tumor efficacy. Perhaps use of less mature myeloid cells capable of trafficking to the tumor microenvironment and regional nodes contributes to the tumor responses we observe. Our dose of 107 IMC per 30 gm mouse corresponds to 3.3×108 cells/kg or 1.7×1010 cells for a 50 kg adult, in contrast to the 109 macrophages used in human trials. This dose should be readily achievable through expansion of marrow CD34+ cells, as human peripheral blood or marrow stem cell harvest typically yields at least 2×106 CD34+ cells/kg,31 and culture of cord blood CD34+ cells with TPO, SCF, FL, IL-6, IL-3, and Notch Ligand for 14–16 days leads to almost 1,000-fold expansion.32 We have seen similar expansion on culture of adult marrow CD34+ cells with TPO, SCF, FL, and IL-6, SR1, and UM171, which was increased to more than 100,000-fold by continued culture. Of note, we have seen no toxicity of p50-IMC in tumor-bearing mice.
p50 directly represses the genes encoding pro-inflammatory TNFα, IL-8, Mmp13, Cox-2, Ccl2, Ccl10, GM-CSF, and IFNβ and induces the gene encoding anti-inflammatory IL-10.33–37 Deletion of p50 in IMC likely impacts these factors and contributes to activation of resulting macrophages and DCs.9–16 Consistent with this idea, we find that p50-IMC generate tumor and lymph node macrophages that co-express Ly6C and MHCII, a combination indicative of activated, tumor suppressive macrophages.28 38–40 We previously found increased Ly6C+MHCII+ tumor macrophages in glioblastomas developing in the central nervous system of p50-/- compared with WT hosts, associated with reduced glioblastoma tumor growth.16 We also find that p50-IMC generate tumor and lymph node CD11b+F4/80-CD11c+MHCII+ cDCs, which are likely also activated due to de-repression of pro-inflammatory NF-κB target genes. Of note, p50-IMC did not activate endogenous tumor myeloid cells. Adoptive transfer of monocytes expressing exogenous IFNα leads to anti-tumor responses in breast cancer and glioblastoma models.41 42 p50-IMC might be even more effective due to activation of a broad pro-inflammatory gene expression programme consequent to absence of NF-κB p50.
In addition to PCa and PDC, p50-IMC has the potential to contribute to the therapy of multiple malignancies. For clinical translation, we envision gene editing of patient marrow or peripheral blood CD34+ cells as they expand in TPO, SCF, and FL, followed by culture for 1 day in M-CSF or other myeloid cytokines. Patient-derived induced pluripotent stem cells engineered to lack p50 might alternatively serve as a continuous p50-IMC source.
5FU followed by adoptive transfer of p50-IMC slows the growth of murine prostate and PDC. Infused myeloid cells generate activated tumor and lymph node macrophages and DCs and induce CD8+ T cell-mediated anti-tumor immunity. Adoptive transfer of patient-derived NF-κB p50-deficient IMC, potentially generated by expansion and gene editing of marrow CD34+ cells, may contribute to the therapy of these and additional cancers.
We thank Brian W Simons for the B6 Hi-Myc PCa cell line and Surinder K Batra for the B6 UN-KC-1641 K-RasG12D;Pdx1-Cre PDC cell line.
Contributors Study design, manuscript preparation and final approval of manuscript: all authors. Study conduct, data collection and data analysis: RS, DJB, TB and ADF.
Funding This work was supported by a V Foundation Translational Award (ADF), by Department of Defense grant PC150202 (ADF), by National Institutes of Health grants T32 CA60441 (DJB) and P30 CA006973, and by The Giant Food Children’s Cancer Research Fund.
Competing interests ADF is a named inventor on a PCT patent application entitled 'NF-κB p50 Deficient Immature Myeloid Cells and Their Use in Treatment of Cancer' filed by The Johns Hopkins University.
Patient consent for publication Not required.
Ethics approval This study was approved by the Johns Hopkins University Animal Care and Use Committee (protocol M016M66, 03/04/2016).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon reasonable request. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.